-
1.发明公开
公开(公告)号：EP3501538A1
公开(公告)日：2019-06-26
申请号：EP18211423.1
申请日：2007-11-30
发明人： MCEVER, Rodger P , ALVAREZ, Richard , KAWAR, Ziad
IPC分类号： A61K39/395 , C07K16/28
摘要： The invention features antibodies, e.g., chimeric and humanized antibodies, that recognize (i.e., bind) P-selectin. The P-selectin antibodies prevent P-selectin from binding to its cognate receptor. The P-selectin antibodies can be used to treat inflammatory and thrombotic conditions, e.g., sickle cell disease, pain crisis associated with sickle cell disease, deep vein thrombosis, asthma, rheumatoid arthritis, psoriasis, and ischemia reperfusion injury in a patient in need thereof.
-
公开(公告)号：EP3353329A1
公开(公告)日：2018-08-01
申请号：EP16849780.8
申请日：2016-09-23
申请人： Oklahoma Medical Research Foundation , The Board of Trustees of the Leland Stanford Junior University
CPC分类号： G01N33/6896 , A61K38/215 , G01N33/6863 , G01N33/6866 , G01N33/6869 , G01N2333/565 , G01N2800/285 , G01N2800/52 , G06F19/00 , G06F19/18 , G06F19/24 , G16H50/20 , Y02A90/26
摘要： Disclosed herein are methods in which an individual with multiple sclerosis (MS) can be classified into one of six subject groups, each subject group predictive for the patient's responsiveness to an interferon-β (IFN-β) therapy. The individual with MS can be classified according to the individual's serum marker levels, e.g., at baseline or following treatment with therapy. Depending on the classification, the individual with MS can be treated with standard therapies (e.g. IFN-β) or one or more alternative therapies with or without IFN-β.
-
3.发明公开
公开(公告)号：EP3340972A1
公开(公告)日：2018-07-04
申请号：EP16847184.5
申请日：2016-09-14
IPC分类号： A61K31/15 , A61K31/221 , A61P25/00
CPC分类号： A61K49/10 , A61K31/10 , A61K31/15 , A61K47/20 , A61K2300/00
摘要： Disclosed here is a method of transporting a therapeutic or diagnostic agent across a blood-brain barrier or a blood-cochlear barrier or a blood-cerebrospinal fluid barrier of a subject, comprising administering to a subject an amount of a therapeutic and/or diagnostic agent, along with an amount of 2,4-disulfonyl a-phenyl tertiary butyl nitrone (2,4-DSPBN), said therapeutic and/or diagnostic agent being characterized as being unable or poorly able, in the absence of said amount of 2,4-DSPBN, to cross the blood-brain barrier or the blood-cochlear barrier or the blood-cerebrospinal fluid barrier of said subject.
-
4.发明公开BIOMARKERS FOR SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY, AND INTENSITY AND FLARE 有权生物标志物疾病活动，力度和系统性红斑狼疮的存在
公开(公告)号：EP3052193A1
公开(公告)日：2016-08-10
申请号：EP14851316.1
申请日：2014-10-02
CPC分类号： G01N33/564 , C12Q1/6883 , C12Q2600/118 , C12Q2600/158 , G01N33/6863 , G01N2800/104 , G01N2800/52
摘要： The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.
摘要翻译： 本发明涉及生物标记物的鉴定是预测阻碍做全身性红斑狼疮（SLE）疾病耀斑。 提供了治疗患者因此作为鉴定方法。
-
5.发明公开
公开(公告)号：EP2895184A1
公开(公告)日：2015-07-22
申请号：EP13836620.8
申请日：2013-09-12
发明人： XIA, Lijun
CPC分类号： A61K38/17 , A61K31/661 , A61K38/00 , A61K45/06 , C07K14/47 , C07K16/18 , C07K16/2851 , C07K2317/76 , C12N15/113 , C12N2310/14
摘要： The present invention relates generally to the use of modulators of podoplanin (PDPN) mediated platelet activation. For example, an agonist or mimic of podoplanin (PDPN)/C-type lectin-like receptor 2 (CLEC-2) signaling may be used to inhibit vascular leakage or promote vascular integrity. Alternatively, an antagonist of podoplanin (PDPN)/C-type lectin-like receptor 2 (CLEC-2) signaling may be used to inhibit platelet activation.
-
6.发明授权Hematopoietic stem cells treated by in vitro fucosylation and methods of use 有权与该体外Fucolysierung处理造血干细胞，和使用的方法
公开(公告)号：EP2327760B1
公开(公告)日：2014-04-23
申请号：EP10181456.4
申请日：2004-03-03
发明人： Xia, Lijun , McEver, Rodger P.
IPC分类号： C12N5/00 , C12N5/0789 , A61K35/12
CPC分类号： A61K35/28 , A61K2035/124 , C12N5/0006 , C12N5/0634 , C12N5/0647
摘要： A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an ±1,3-fucosyltransferase, e.g., ±1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other ligans on the cell surface into functional forms that bind selectins, especially P-selectin or E-selectin. The treated cells have enhanced effectiveness in reconstituting bone marrow in patients in need of such therapy.
-
公开(公告)号：EP2446894A3
公开(公告)日：2013-02-20
申请号：EP11185682.9
申请日：2005-10-27
发明人： Brennan, Miles B. , Dores, Robert M. , Haskell-Luevano, Carrie , Hochgeschwender, Ute H. , Costa, Jessica I.
CPC分类号： C07K14/695 , A61K38/00
摘要： ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secretion by adrenal membrane in the presence of the ACTH analog compared to unmodified ACTH, (2) reduction of corticosteroid secretion by adrenal membrane in the presence of endogenous ACTH and (3) increased MC-2R binding affinity with reduced activation of the MC-2R receptor compared to unmodified ACTH binding to the MC-2R melanocortin. The ACTH analog compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders related to ACTH, ACTH receptors or corticosteroid secretion, such as premature labor and Cushing's Disease.
-
8.发明授权HEMATOPOIETIC STEM CELLS TREATED BY IN VITRO FUCOSYLATION AND METHODS OF USE 有权在体外经处理岩藻糖化造血干细胞和使用方法
公开(公告)号：EP1668109B1
公开(公告)日：2013-01-02
申请号：EP04716880.2
申请日：2004-03-03
发明人： Xia, Lijun , McEver, Rodger P.
IPC分类号： C12N5/00
CPC分类号： A61K35/28 , A61K2035/124 , C12N5/0006 , C12N5/0634 , C12N5/0647
摘要： A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an ±1,3-fucosyltransferase, e.g., ±1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other ligans on the cell surface into functional forms that bind selectins, especially P-selectin or E-selectin. The treated cells have enhanced effectiveness in reconstituting bone marrow in patients in need of such therapy.
-
公开(公告)号：EP2470015A1
公开(公告)日：2012-07-04
申请号：EP10814226.6
申请日：2010-08-24
CPC分类号： A61K31/10 , A61K9/0053 , A61K31/15 , A61K31/198 , A61K45/06 , A61K2300/00
摘要： The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition 2,4-disulfonyl α-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). Preferably, the compositions for treating AAT will be administered orally. However, other methods which deliver the compositions for treating AAT systemically to the body should work equally well.
-
10.发明授权METHOD OF USING CYTOKINE ASSAYS TO DIAGNOSE, TREAT, AND EVALUATE ANKYLOSING SPONDYLITIS 有权方法CYTOKINTESTS的诊断，治疗和评价ANKYLOIDER炎使用
公开(公告)号：EP1664796B1
公开(公告)日：2010-12-15
申请号：EP04788750.0
申请日：2004-09-15
IPC分类号： G01N33/68
CPC分类号： G01N33/6863 , G01N33/564 , G01N2800/104 , G01N2800/24 , G01N2800/52
摘要： The invention provides methods for diagnosing, treating, or evaluating inflammatory and autoimmune diseases by sampling peripheral blood, serum, plasma, tissue, cerebrospinal fluid, or other bodily fluids from a human subject having a suspected diagnosis. The sample is analyzed for the presence and amount of certain cytokines, which provides the diagnosis, prognosis or 10 evaluation of therapeutic response.
-
-
-
-
-
-
-
-
-
搜索结果
199 条记录 (耗时 0.036 秒)
